Articles tagged with Osteoporosis
A Phase 2 trial of denosumab found significant increases in bone mineral density across various sites, including the lumbar spine, total hip, and distal radius. The study suggests denosumab may offer a new approach to treating osteoporosis by targeting RANK Ligand.
Five organizations have won US$10,000 each for imaginative education projects focused on osteoporosis prevention and management. These grants will support public education materials, campaigns, and awareness initiatives across Indonesia, Iran, Jordan, Panama, and Taiwan.
The event aimed to raise awareness about the importance of maintaining strong bones, particularly for young people, who can build peak bone mass between ages 11-17. Experts stressed the need for proper diet, exercise, and lifestyle habits to reduce the risk of osteoporosis, which affects one in three women over 50 worldwide.
Researchers propose a two-stage screening approach to identify individuals with low bone mineral density and increased risk of osteoporotic fractures. This could lead to improved cost-effectiveness in treatment, reducing the economic burden of fractures on individuals and society.
Researchers at UCLA used a drug to block mutant proteins from deforming cell nuclei, significantly reducing misshapen nuclei in human cells. The findings offer new clues into how progeria develops and could lead to treatment with new drugs for related disorders like osteoporosis.
A Purdue study found that increasing calcium intake by 200-300mg per day can significantly boost bone mineral density in young women taking oral contraceptives, reducing the risk of osteoporosis. The researchers suggest that this simple change can prevent a significant loss of bone mass, particularly during peak bone development years.
A new study shows that combining parathyroid hormone and alendronate for a year followed by a year increases bone density significantly more than other treatments, providing sustained gains. The treatment has the potential to offer the largest gains in bone density yet available at a lower cost than using parathyroid hormone alone.
Standard clinical practice guidelines often focus on one disease and exclude coexisting conditions, leaving clinicians without guidance for caring for older patients with multiple chronic diseases. This can lead to polypharmacy, medication errors, and an unsustainable treatment burden.
Vertebroplasty and kyphoplasty treatments offer pain relief for osteoporosis sufferers, with the National Osteoporosis Foundation estimating 44 million Americans over 50 affected. The procedures stabilize fractured bones and prevent movement, providing significant cost savings.
A study published in JAMA found that black women had a significantly lower risk of fractures than white women at every level of bone mineral density. Despite this, researchers emphasize the importance of considering individual factors such as body weight and other risk factors when assessing fracture risk.
A study found that 1 in 6 elderly patients with clinically important vertebral fractures had unreported osteoporosis diagnoses, highlighting the need for better screening and treatment strategies.
Researchers at Yale University identified IRAK-M as a key regulator of bone cells, finding that its presence prevents bone loss and its absence leads to severe osteoporosis in mice. The study suggests IRAK-M could be a new target for treating or preventing osteoporosis.
Researchers found that a peptide called GPCS significantly inhibited bone mineral loss in isolated bone cells from newborn rats. Additional studies are needed to determine the mechanism of action and effectiveness of GPCS on human bone health.
A study shows that lidocaine patch 5% and celecoxib achieved significant reductions in pain intensity, with 62% of patients in the celecoxib group experiencing a 30% or greater improvement. The findings offer hope for OA patients seeking alternative pain relief options.
A study of strict raw food vegans found they had lower body mass indices and significantly lower bone mass, but normal markers of bone turnover. They also had higher-than-normal vitamin D levels and low inflammation.
Researchers found that patients with osteoporosis had a significantly higher prevalence of celiac disease than those without osteoporosis. Treatment with a gluten-free diet resulted in improved bone mineral density in individuals with celiac disease and osteoporosis, making serologic screening worthwhile for this population.
A recent study suggests that patients with osteoporosis may have coexisting celiac disease, which can lead to impaired calcium and vitamin D absorption. Screening for celiac disease in patients with osteoporosis may be recommended to correct bone loss.
A recent study of 1,323 women reveals a significant gap in osteoporosis treatment based on fracture history. Women with past fractures are at a higher risk of future osteoporosis, emphasizing the importance of considering fracture history in treatment decisions.
Research demonstrates that the sympathetic nervous system mediates bone resorption through a receptor on bone cells, which is required for osteoporosis development. Preventing this effect could lead to the prevention of osteoporosis. Drugs like beta blockers show promise in reducing fractures and may be repurposed to target bone health.
Researchers at the Friedman School of Nutrition Science and Policy at Tufts University have identified two variants in the perilipin gene associated with increased obesity risk in white women. Vitamin B12 deficiency has also been linked to lower bone mineral density, increasing the risk of osteoporosis.
Researchers found a genetic variant of the CYP1A1 gene associated with lower estrogen levels, higher bone resorption markers, and lower bone density in hip bones. This variant may serve as an important genetic marker for identifying women at high risk of osteoporosis.
A study of 3,107 older adults found that screening for osteoporosis using a bone density test reduced the incidence of hip fractures by 36% compared to usual medical care. The study provides new evidence for the effectiveness of osteoporosis screening in preventing fractures.
A new study by Ohio State University researchers found that calcium supplementation significantly increased bone mass development during a critical childhood growth spurt in pre-adolescent girls. The findings suggest that elevated calcium use during this period may help prevent fractures and osteoporosis later in life.
A study found that prostate cancer patients receiving androgen deprivation therapy were at high risk of osteoporosis, yet few received prevention or treatment. Only primary care physicians were aggressive in managing osteoporosis risk.
A study found that dental x-rays were as sensitive as questionnaires in identifying women with spinal osteoporosis. Dental x-rays can be used as a first step in determining which women need further BMD testing, especially for those with low response rates to questionnaires.
Researchers at Tufts University found a significant gap in care for fracture patients, with few treated for osteoporosis despite increased risk of re-fracture. The study suggests that primary care physicians play a crucial role in reducing this risk through targeted counseling and medication.
A Phase 2 trial showed AMG 162 increased bone mineral density at the hip, spine, and total body by 4-7% compared to FOSAMAX®. The therapy was well-tolerated with a common adverse event of dyspepsia.
A study of postmenopausal women found that nearly half had vitamin D levels below the threshold, highlighting the importance of adequate supplementation and proper exposure to sunlight. Vitamin D plays a crucial role in osteoporosis management by promoting calcium absorption and resorption.
Researchers are using genetically engineered 'mighty mice' to study the relationship between muscle and bone health. They hope to find a way to build bone and avoid osteoporosis in young people. Early evidence suggests that exercise may not have as much of an impact on bone density as previously thought.
Quantitative sonography and DXA have differing diagnoses for osteoporosis in patients, with limited correlation between the two methods. The study suggests that quantitative sonography may not be suitable to replace DXA measurements for diagnosing osteoporosis due to low correlation.
Osteoporosis patients in US saw a four-fold rise in doctor visits from 1994 to 2003, driven by new medication availability. This trend shows improved treatment options for osteoporosis, but highlights the need for prevention strategies such as calcium use and physical activity.
A Stanford study estimates that fewer than half of people with osteoporosis have been diagnosed, highlighting the need for better screening and treatment. The study found that new prescription medications have improved diagnosis and treatment rates, but more work is needed to catch cases early.
Researchers propose adding calcium and vitamin D to existing FDA-mandated enrichment mix in products like bread and pasta to reduce osteoporosis and colon cancer incidences. The measure could save 11,000 lives and $3 billion annually with minimal financial cost.
The absence of platelet-activating factor receptor in mice with induced menopause leads to improved bone mineral density and volume. Osteoclasts are responsible for PAF's mechanism of action, and inhibiting PAF receptor function reduces bone resorption.
Researchers at CAMOS found a significant 'osteoporosis care gap,' with many cases going undetected in older adults. The study also revealed that even diagnosis can lead to a decline in quality of life due to fear of fractures.
Dr. Charles Pak, a renowned researcher, has been recognized with an international award for his groundbreaking work on kidney-stone disease treatment methodologies. He has developed several drugs used worldwide and diagnostic methods for measuring risk factors, improving patient outcomes.
Research finds that mitochondrial function decline is a critical mechanism driving aging, leading to premature aging in mice. The study highlights the potential for protecting mitochondrial DNA from damage to slow down aging and treat related pathological changes.
Researchers analyzed data from 149,524 postmenopausal women to identify predictors of bone fractures. Women with low T scores or previous fractures were found to be at increased risk, highlighting the need for targeted interventions.
A recent study found that height loss of between 2-3 inches increases the risk of hip osteoporosis by nearly fourfold. Researchers suggest a simple evaluation of height can help physicians decide whether patients should undergo a bone density scan to check for osteoporosis.
A statistical model predicts rapid increase in spinal fractures over time if left untreated, highlighting the importance of intervention before first fracture occurs. The study emphasizes the need for therapy that reduces risk of first fracture within one year to substantially reduce future fracture risk.
A randomized trial compared the effects of raloxifene and CEE on bone mineral density in postmenopausal women with prior hysterectomy. The study found that CEE increased bone density by 4.6%, while raloxifene stabilized bone density, and both treatments had varying impacts on cholesterol levels.
A study by University of Alberta researchers found that 22 patients had vertebral fractures, with 45% going undiagnosed. Vertebral fractures often indicate osteoporosis, a common disease in the elderly that can be easily treated with drugs.
A Baylor College of Medicine study reveals that the hormone amylin inhibits bone loss and resorption. Mice without amylin have less bone mass due to increased bone destruction, suggesting a potential therapeutic avenue for preventing osteoporosis in Type 1 diabetes patients.
A study published in Science has identified the Alox15 gene as a potential human therapeutic target for osteoporosis risk. The gene's over-activity leads to reduced bone density and increased risk of osteoporosis, but inhibitors of the gene's enzyme can improve bone mass and strength.
A study identified variants of the BMP2 gene as genetic risk factors for osteoporosis, approximately tripling the likelihood of developing the disease. The findings were replicated in an independent cohort, suggesting a strong association between the gene's variants and increased risk of osteoporotic fractures.
Two studies found that combining parathyroid hormone (PTH) and alendronate increases bone mineral density (BMD) at least as well as or better than single drug treatment. Further studies are needed to determine the optimal effects of these drugs, particularly through sequential or cyclic therapy.
A new study found that Actonel maintained the size of calcium-based mineral crystals and the integrity of collagen structure over five years, preserving bone quality. This is significant because osteoporosis therapies should aim to reduce fracture risk, not just treat symptoms.
A new study found that combining osteoporosis medications, parathyroid hormone and bisphosphonates, does not provide additional benefits to patients. The trial of 238 postmenopausal women showed no significant improvement in bone density or anabolic effects when both drugs were used together.
A recent study by Massachusetts General Hospital found that combining osteoporosis treatments does not produce better results. Injections of PTH, a treatment initially developed through MGH research, increase bone formation and were superior to alendronate alone in improving bone density.
A study conducted at the University of Melbourne found that smoking is significantly linked to osteoporosis in women, particularly after menopause. Continuing high exposure to tobacco and greater sensitivity to smoking-induced bone loss are possible explanations for this link.
Researchers at Purdue University have developed a new tool using dual energy X-ray absorptiometry (DEXA) to accurately determine bone mineral density in hens. The study found that more calcium resulted in greater bone mineral density and stronger bones, leading to potential improvements in egg production.
Researchers highlight the growing concern of male osteoporosis, emphasizing genetic predispositions and secondary risk factors such as alcohol consumption and malnutrition. Dr. Rosen recommends early bone density testing for men over 55 with unexplained height loss or fracture history to identify potential treatment options.
A study analyzing data from pivotal trials of Actonel revealed that bone mineral density explains only a small portion of nonvertebral fracture risk reduction. The analysis found that BMD increases accounted for just 12.2% of the fracture risk reduction at lumbar spine, and 5.5% at femoral neck.
A 7-year study shows Actonel significantly reduces vertebral fracture incidence, with annualized rates of 4.7%, 5.2%, and 3.8% for the treatment group, respectively. Adverse events were similar to those in patients taking placebo during the first 5 years.
A new study published in JAMA found that a combination therapy of hormone replacement and alendronate was well-tolerated by elderly women with low bone mass. After three years, participants taking the combination therapy showed significantly greater increases in bone mass compared to those taking individual therapies.
A recent study evaluated the medical costs of osteoporosis therapies and found that patients taking weekly Fosamax had lower GI-related medical costs compared to those taking daily or weekly doses. The analysis, conducted with a large medical claims database, also revealed that treating patients with a weekly dose of Fosamax versus a d...
A study found that mice genetically engineered to lack a molecule called Stem Cell Antigen-1 (Sca-1) experienced normal bone development but exhibited decreased bone mass and brittle bones as they aged. The researchers believe that defective maintenance of stem cells may contribute to age-related osteoporosis in humans.
A University of Pittsburgh study found significant imbalance in bone turnover among post-operative patients undergoing stomach-reduction surgery, resulting in up to an 8% drop in bone density. The researchers suggest that major weight loss requires ongoing calcium and vitamin supplementation for bone health.
Actonel significantly reduced fracture risk in high-risk postmenopausal women, with a 62% reduction seen at one year. The medication was found to be effective in reducing spinal fractures in patients over 70 years old and those with low hip BMD.
Researchers at the University of Pittsburgh discovered that PTHrP significantly increases bone mineral density in postmenopausal women with osteoporosis, with a 4.7% increase observed in just three months. The study's findings are promising and take the identification of an effective short-term anabolic agent one step further.